Bayer plans filings for cardiac amyloidosis imaging agent
Armed with new phase 3 data, Bayer is preparing to file a PET imaging agent that could accelerate the diagnosis of cardiac amyloidosis.
Roche buys AI-powered diagnostics player PathAI
Roche has been working with US AI specialist PathAI for around five years, and has now upgraded that partnership with an offer to buy it for $1.05bn.
Mike Guarino appointed to lead EVERSANA INTOUCH
Life sciences service provider EVERSANA has named industry veteran Mike Guarino to lead its global health agency EVERSANA INTOUCH.
Angelini seeks US beachhead with $4.1bn Catalyst buy
Angelini has agreed to buy Catalyst Pharma for up to $4.1bn, its first acquisition since 2021, which would mark its entry into the US market.
Lilly inflates US facility investment spending by $4.5bn
Having already committed last year to capital investments of $27 billion in the US to ward off the threat of tariffs, Eli Lilly has upped the ante.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
Navigating Change: Key Industry Insights at PHARMAP 2026
PHARMAP returns in 2027 in Berlin, Germany, with Bayer as the Host Sponsor
Xcovery Partners with EVERSANA to Commercialize Lung Cancer ...
EVERSANA will provide comprehensive end-to-end commercialization services for Xcovery
Axtria Acquires Conexus Solutions, Uniting Agentic AI and CR...
Axtria Inc., a global leader in AI-first data analytics solutions for the life sciences industry, today announced the acquisition of Conexus Solutions
PHARMAP 2026: From Vendors to Strategic Partners
Strategic Partnerships at PHARMAP 2026 – Big Pharma’s Shift Toward CDMOs and CMOs
WOMA 2026: Steering the Future of Pharma Strategy
The WOMA Forum is not merely a conference. It's a convergence point for decision-makers